Northern Trust Corp Takes Position in Inhibrx, Inc. (NASDAQ:INBX)

Northern Trust Corp acquired a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 116,104 shares of the company's stock, valued at approximately $1,788,000. Northern Trust Corp owned about 0.80% of Inhibrx as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of INBX. Exchange Traded Concepts LLC purchased a new position in shares of Inhibrx in the 4th quarter valued at approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in shares of Inhibrx during the fourth quarter worth $348,000. China Universal Asset Management Co. Ltd. purchased a new position in Inhibrx in the 4th quarter valued at $47,000. Rhumbline Advisers acquired a new position in Inhibrx in the 4th quarter valued at $228,000. Finally, New York State Common Retirement Fund purchased a new position in Inhibrx during the 4th quarter worth $53,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research note on Thursday, May 15th.

Inhibrx Stock Performance

NASDAQ:INBX traded down $0.25 during mid-day trading on Friday, reaching $13.51. The stock had a trading volume of 51,910 shares, compared to its average volume of 119,676. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $18.95. The business has a 50 day simple moving average of $12.41 and a 200 day simple moving average of $13.48. The firm has a market capitalization of $195.50 million and a price-to-earnings ratio of 0.12.

Inhibrx (NASDAQ:INBX - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). As a group, sell-side analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current year.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.